NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-12-30 | ||
| Revenue | — | 2.3M |
| EPS | — | -2 |
| Annual ending 2026-12-31 | ||
| Revenue | — | 80.26M |
| EPS | — | 27.4 |
Management figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
management remains stable and executes turnaround plan | A supporting condition in Precipio Inc's published investment case. The stated target is management remains stable through 2026. | Intact | significant management turnover or disruption occurs | No turnover reported News shows consistent earnings calls and no leadership changes; metric is qualitative and remains intact. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
improve profit margins from current loss-making status | A primary condition in Precipio Inc's published investment case. The stated target is reduce losses and move toward positive margins by FY26. | Improving | losses widen or margins fail to improve by FY26 | Net margin: -3.12% FY2026-Q2; GAAP. Published target: reduce losses and move toward positive margins by FY26. Target percentage unit is not explicit. Source published Aug 14, 2026-3.119214 percent · calculatedSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ad5447fb-4776-4ef4-a197-85264c994db7. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
annual revenue reaches at least $24 million in 2025 | Precipio is growing revenue with a target of at least $24 million in 2025. | Improving | annual revenue falls below $24 million in 2025 | Revenue: $7.021M FY2026-Q2; GAAP. Published target: >=24 USD_MILLIONS. Target period is not explicitly aligned with this observation. Source published Aug 14, 20267,021,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ad5447fb-4776-4ef4-a197-85264c994db7. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk growth and profitability-improvement story, not a proven durable compounder. The long-term thesis is intact, with management delivering revenue growth but showing mixed progress in reducing losses.
The evidence characterizes PRPO as cheap versus peers, while also showing a 29% premium versus peers and a low-confidence valuation model. The priced-in tag is justified, with no flagged fragility, but the negative expectations gap points to limited room for execution to fall short of what is assumed.
Over the multi-year view, revenue growth and positive operating cash flow support progress toward management’s goal of adjusted EBITDA profitability. Profitability remains volatile, and the recent quarter was missed, leaving elevated near-term earnings risk.
The next earnings call is a key near-term test: a guidance cut would weaken the thesis. A weakening jobs report could also pressure cyclical healthcare names, while continued strong results and guidance from sector bellwethers could support the sector backdrop.
Over the next 1 to 3 years, PRPO’s thesis rests on turning revenue growth into steadier profitability while managing high earnings and economic risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.